Arcutis Biotherapeutics

ARQT

Market cap $2.5B

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere on the body for any duration About 1.8 million children ages 2 to 5 with atopic dermatitis are topically treated in the U.S. Sixth FDA approval for ZORYVE in just over three years Commercial product expected to be available by the end of October 2025 WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.

WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units of Arcutis' common stock to 12 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial results on Tuesday, October 28, 2025, before the U.S. financial markets open.

Biotech leader Arcutis stock is breaking out past its latest buy point. Shares are up nearly 36% in 2025.

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin types New data show improved quality of life and decreased impact on families for investigational ZORYVE cream 0.05% in children aged 2–5 years with atopic dermatitis Data demonstrate both ZORYVE cream 0.3% and ZORYVE foam 0.3% improved signs and symptoms of plaque psoriasis in individuals with facial and/or genital involvement WESTLAKE VILLAGE, Calif. and PARIS, Sept.

First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough Award” ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined—eczema, plaque psoriasis, and seborrheic dermatitis Cream and leave-in foam options are uniquely formulated to be used anywhere on the body once per day and on diverse skin and hair types ZORYVE was shown to be safe and well-tolerated and to provide rapid and reliable symptom relief and has been chosen by healthcare providers over 1 million times WESTLAKE VILLAGE, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE was presented with a 2025 Best of Beauty Breakthrough Award by Allure magazine, which is globally recognized as the most distinguished beauty award by industry professionals and consumers.

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)